Company Overview and News

2
ALT / Altimmune, Inc. 8-K (Current Report)

8h sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
ALT

2
ALT / Altimmune, Inc. PRE 14A

8h sec.gov
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D
ALT

11
Gemphire Therapeutics: Financing Likely, NASH/NAFLD Opportunity In Focus

2018-07-02 seekingalpha
Data for the proof-of-concept study in FPL/NASH and results from the pediatric NAFLD trial are important catalysts to look forward to.
GEMP ALT

20
ALT / Altimmune, Inc. 8-K (Current Report)

2018-06-25 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
ALT

11
ALT / Altimmune, Inc. FORM 8-K (Current Report)

2018-06-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
ALT

11
ALT / Altimmune, Inc. 8-K (Current Report)

2018-05-18 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
ALT

4
Altimmune's (ALT) CEO Bill Enright on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Good day and welcome to the Altimmune First Quarter 2018 Earnings Conference Call. Today’s conference is being recorded, and at this time, I would like to turn it over to (inaudible). Please go ahead.
ALT

23
ALT / Altimmune, Inc. FORM 8-K (Current Report)

2018-05-15 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
ALT

14
ALT / Altimmune, Inc. 10-Q (Quarterly Report)

2018-05-15 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ALT

11
ALT / Altimmune, Inc. 8-K (Current Report)

2018-05-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
ALT

29
ALT / Altimmune, Inc. FORM 10-K/A (Annual Report)

2018-04-30 sec.gov
Form 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C
ALT

133
Conatus Pharmaceuticals: Upcoming Phase 2b Liver Results And Other Pipeline Prospects Make It A Compelling Buy

2018-04-24 seekingalpha
Conatus Pharmaceuticals has results for its phase 2b ENCORE-PH study coming out by the second half of 2018.
AGN CNAT NVS ALT

132
Conatus Pharmaceuticals; Upcoming Phase 2b Liver Results And Other Pipeline Prospects Makes It A Compelling Buy

2018-04-24 seekingalpha
Conatus Pharmaceuticals has results for its phase 2b ENCORE-PH study coming out by the second half of 2018.
AGN CNAT NVS ALT

4
ALT / Altimmune, Inc. 10-K (Annual Report)

2018-04-02 sec.gov
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ALT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

35m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ALT / Altimmune, Inc. on message board site Silicon Investor.

Alternative energy A US National Health Care System?
Plastics to Oil - Pyrolysis and Secret Catalysts and Alterna Reliq Health Technologies Inc
Altaba Inc. (formerly Yahoo) Stayhealthy.com: Monitoring your wellness on the Web
Female Health FHCO Palo Alto Networks, Inc.
Gemalto N.V. The World���s Biggest Wealth Fund Hits $1 Trillion
CUSIP: 02155H101